Alnylam Pharmaceuticals and Inceptive Nucleics are involved in strategic developments, including trading on the exchange and pursuing collaborations to accelerate therapeutics innovation.
1 report, 1 independent
Updated Jun 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alnylam Pharmaceuticals and Inceptive Nucleics are involved in strategic developments, including trading on the exchange and pursuing collaborations to accelerate therapeutics innovation.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
-
Nasdaq
American fully electronic stock exchange
Related events
- Alnylam Pharmaceuticals (listed on Nasdaq) and Emergent BioSolutions (listed on NYSE) are two healthcare companies competing for investment.
- Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.